热点
"GLP-1受体激动剂" 相关文章
礼来：将在荷兰投资30亿美元新建生产基地，扩大口服药物产能
36氪 - 快讯 2025-11-04T00:05:55.000000Z
礼来：将在荷兰投资30亿美元新建生产基地，以扩大口服药物产能
界面快报 2025-11-03T14:25:40.000000Z
The Biochemical Beauty of Retatrutide: How GLP-1s Actually Work
少点错误 2025-10-14T16:35:53.000000Z
Lilly to site next US manufacturing facility in Texas
News - European Pharmaceutical Review 2025-09-29T02:49:28.000000Z
Nearly all Medicare Part D plans require prior auth for GLP-1s
WhatIs.com 2025-09-29T02:49:09.000000Z
#314 ‒ Rethinking nutrition science: the evolving landscape of obesity treatment, GLP-1 agonists, protein, and the need for higher research standards | David Allison, Ph.D.
The Peter Attia Drive 2025-09-25T10:01:52.000000Z
#314 ‒ Rethinking nutrition science: the evolving landscape of obesity treatment, GLP-1 agonists, protein, and the need for higher research standards | David Allison, Ph.D.
The Peter Attia Drive 2025-09-25T10:01:52.000000Z
#333 ‒ Longevity roundtable — the science of aging, geroprotective molecules, lifestyle interventions, challenges in research, and more | Steven Austad, Matt Kaeberlein, Richard Miller
The Peter Attia Drive 2025-09-25T10:01:29.000000Z
#337 - Insulin resistance masterclass: The full body impact of metabolic dysfunction and prevention, diagnosis, and treatment | Ralph DeFronzo, M.D.
The Peter Attia Drive 2025-09-25T10:01:29.000000Z
研究人员警告称Ozempic等热门减肥药对年轻女性存在隐藏风险
Cnbeta 2025-09-12T05:34:55.000000Z
礼来：口服GLP-1RA orforglipron平均减重降幅高达12.4kg
界面快报 2025-08-07T13:00:34.000000Z
诺和诺德：诺和泰®新增慢性肾脏病适应症
36氪 2025-07-18T12:00:05.000000Z
诺和诺德：诺和泰®新增慢性肾脏病适应症
深度 2025-07-18T11:48:45.000000Z
诺和诺德司美格鲁肽注射液慢性肾脏病适应症在华获批
界面快报 2025-07-18T11:43:58.000000Z
诺和诺德：司美格鲁肽注射液新增慢性肾脏病适应症在华获批
e公司-快讯 2025-07-18T11:27:06.000000Z
48周减重15.1%，药效堪比礼来！中国原研的“减肥神药”来了
华尔街见闻 - 最热文章 2025-06-22T12:10:06.000000Z
#337 - Insulin resistance masterclass: The full body impact of metabolic dysfunction and prevention, diagnosis, and treatment | Ralph DeFronzo, M.D.
The Peter Attia Drive 2025-02-24T05:24:48.000000Z
南加州大学研究发现司美格鲁肽可抑制对酒精的渴望
Cnbeta 2025-02-21T08:36:59.000000Z
上海自研GLP-1糖尿病新药开出首张处方，或将挑战司美格鲁肽
深度财经头条 2025-02-11T05:49:27.000000Z
擔心落後於禮來，諾和諾德印度團隊據悉敦促提前推出Wegovy
富途牛牛头条 2024-12-03T13:34:31.000000Z